Braveheart Bio, Inc. (NASDAQ:BRVE)
| Market Cap | $1.39B-34.2% |
| Revenue (ttm) | $0 |
| Net Income | -$62.22M |
| EPS | -$2.89 |
| Shares Out | 70.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 536,604 |
| Open | $20.41 |
| Previous Close | $20.50 |
| Day's Range | $19.19 - $20.41 |
| 52-Week Range | $16.70 - $32.00 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | $45.25(+130.63%) |
| Earnings Date | Feb 9, 2027 |
About BRVE
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
When insiders bought and sold
1 year · open-market trades onlyAnalyst consensus
1 firm rating BRVE in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 9, 2027Earnings report
$BRVE stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in BRVE holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BRVE's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BRVE Estimated quarterly lobbying spending
Source: U.S. Senate LDA
BRVE Revenue by Segment
| Personnel-related | $14.79M | 78.88% |
| Other | $2.84M | 15.16% |
| License milestones | $1.00M | 5.33% |
| Facilities | $119.00K | 0.63% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New BRVE patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BRVE from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in BRVE
| VTIVanguard Morningstar Total Stock Market ETF | $14.49M |
| VXFVanguard Extended Market ETF | $5.08M |
| SCHASchwab U.S. Small-Cap ETF | $2.38M |
| FSMOFidelity Fundamental Small-Mid Cap ETF | $1.16M |
| FFSMFidelity Fundamental Small-Mid Cap ETF | $1.16M |
| ONEQFidelity Nasdaq Composite Index ETF | $359.59K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from BRVE’s recent data — informational, not investment advice
What’s Behind the Score
News check: Positive clinical data presentation and business activity announcements support constructive near-term outlook, though mixed investor commentary suggests cautious investor reception.